National and Kapodistrian University of Athens
Κλινική έρευνα για την απόδειξη της ανοσοποιητικόττας και της ανεκτικότητας ενός τετραδύναμου HPV (για του τύπους 6, 11, 16, 18) εμβολίου σε κορίτσια της περιεφηβικής ηλικίας και σε ενήλικες
Abstract
dc:descriptionCervical cancer is directly related with HPV infection and specifically with certain carcinogenic types. Our study has three main aims: 1. Safety: To prove that the quadrivalent HPV vaccine (anti HPV 6, 11, 16, 18), administered in 3 doses is well tolerated by young women. 2. Immunization: To prove that the quadrivalent vaccine, administered in 3 doses, has equally effective anti HPV 6, anti HPV 11, anti HPV 16 and anti HPV 18 results in young women aged 16-23. 3. Immunogenesis: To recognize the minimal pharmaceutical amount of the quadrivalent vaccination in partial and complete doses that will bring forth similar reactions. This study was carried out at the Department of Pediatric and Adolescent Gynecology and Reconstructive Surgery at Areteio University Hospital. The subjects were 10 women aged between 16-23 years. Each woman had her own medical file which contained previous medical history, gynaecological exams and complete description of all visits. Each woman was followed up for a period of 7 months. All women had free gynecologic and obstetric history. They also had normal cervical smear tests. The quadrivalent vaccination was administered in three doses, intramuscularly on day 1, month 2 and month 6 of the study. Prior to each vaccination, each woman underwent a pregnancy test, which was also performed on month 7, 1 month after the last vaccination. No patient showed signs of elevated temperature levels during the 5 days oral temperature measurement (temperatures were <37,8 C). The quadrivalent vaccine was well tolerated, with only mild local side effects being mostly encountered usually at the vaccination point. Local side effects were encountered in 8 women, 3 women had systemic side effects (one woman reported cough, another headaches and another general weakness). The local side effects at the injection site in 3 participants were skin erythaema, slight pain in 5 others (three of which had reported the erythaema), one participant reported swelling and 2 complained of itchiness. None of the women dropped out of the study, or ceased the vaccination process due to adverse systemic effects. The quadrivalent vaccine has proven effective against HPV infections (6, 11, 16, 18) during the five years follow up. The percentage of antibodies that were developed was especially high, specifically those for anti HPV 16. The results of our study show that the quadrivalent vaccination provides strong and long lasting immunity (5 years up to today). Thus, a prophylactic vaccination against HPV 6, 11, 16, 18 can prevent diseases caused by these viruses and should be added to classical immunization regimes and will help to reduce precancerous lesions, condylomas and more importantly cervical cancer. Finally, HPV vaccination will be particularly useful in parts of the world where health care resources are limited. It will greatly reduce treatment costs emanating from cases of cervical cancer.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2007
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Anastassiou-Fotaki, Paraskevi
- Αναστασίου-Φωτάκη, Παρασκευή
Subjects
dc:subject × 17- Εμβόλια, Τετραδύναμα
- Ιοί, Τυποποίηση
- Δυσπλασία
- Ιοί θηλωμάτων του ανθρώπου (HPV)
- Κονδυλώματα
- Προκαρκινική βλάβη
- Αντισώματα
- HPV - Human Papilloma Virus
- LGSIL - Low Grade Squamous Intraepitelial Lesions
- HGSIL - High Grade Squamous Intraepitelial Lesions
- CIN - Cervical Intraepithelial Neoplasia
- VLP - Virus Like Particles
- Antibodies
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/18320